Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
Recombinant human factor IX (rFIX) has been expressed in transduced cultured cell systems since 1985. Because there has been limited in vivo testing of rFIX in hemophilia B subjects, this study was undertaken using the severe hemophilia B canines of the Chapel Hill strain. Three groups of hemophilic dogs received either 50, 100, or 200 IU/kg of rFIX. As a control, a fourth group of hemophilic dogs received 50 IU/kg of a high purity, plasma-derived human FIX (pdFIX). The coagulant and hemostatic effects of rFIX and pdFIX were similar with all comparative dosing regimens. Based on activity data, the elimination half-life of rFIX was 18.9 +/- 2.3 hours and pdFIX was 17.9 +/- 2.1 hours. A prophylactic regimen administering rFIX daily resulted in a continuous therapeutic level of plasma FIX and was accompanied by a two-fold increase in recovery levels by day 5, compared to that observed with administration of a single bolus. The mechanisms of the high to complete recovery of FIX with the prophylactic regimen could depend not only on the degree of saturation of the vascular endothelial binding sites but also on the altered dynamics of the balance of FIX distribution between the intravascular and extravascular compartments. The pharmacokinetic (PK) parameters for rFIX and pdFIX were similar. However, the relative PK values for V1 and V5s of both products on day 5 differed greatly from day 1 and may reflect the changing equilibrium of FIX between compartments with elevated levels of plasma FIX. Neutralizing antihuman FIX antibodies resulting from human FIX antigen being administered to FIX deficient dogs were observed beginning at 14 days. The antigenicity of rFIX and pdFIX appeared to be comparable. Despite the very different procedures used for production of rFIX and pdFIX products, in vivo testing in hemophilia B dogs showed the functional behavior of these products is similar; they are highly effective for replacement therapy and for prophylaxis.
Brinkhous
K M
KM
Department of Pathology, University of North Carolina at Chapel Hill 27599-7525, USA.
Sigman
J L
JL
Read
M S
MS
Stewart
P F
PF
McCarthy
K P
KP
Timony
G A
GA
Leppanen
S D
SD
Rup
B J
BJ
Keith
J C
JC
Garzone
P D
PD
Schaub
R G
RG
D000818:Animals; D000917:Antibody Formation; D004283:Dog Diseases / Q000097:blood / Q000235:genetics / Q000628:therapy*; D004285:Dogs / Q000097:blood / Q000276:immunology; D004341:Drug Evaluation / Q000662:veterinary; D004730:Endothelium, Vascular / Q000378:metabolism; D005164:Factor IX / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002836:Hemophilia B / Q000097:blood / Q000235:genetics / Q000628:therapy / Q000662:veterinary*; D006801:Humans; D007114:Immunization; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013045:Species Specificity
D011993:Recombinant Fusion Proteins; D005164:Factor IX